Johnson & Johnson Defined Benefit Plan, Net Periodic Benefit Cost (Credit)
Johnson & Johnson (JNJ) reported Defined Benefit Plan, Net Periodic Benefit Cost (Credit) of $414.00 million for the 12-month period ending 2012-01-01, per its 10-K filed 2012-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost · last filed 2012-02-23
- Johnson & Johnson defined benefit plan, net periodic benefit cost (credit) for fiscal 2012 was $414.00M, a 40.82% increase from fiscal 2011.
- Johnson & Johnson defined benefit plan, net periodic benefit cost (credit) for fiscal 2011 was $294.00M, a 2.80% increase from fiscal 2010.
- Johnson & Johnson defined benefit plan, net periodic benefit cost (credit) for fiscal 2010 was $286.00M.
| Period end | Defined Benefit Plan, Net Periodic Benefit Cost (Credit) 12 month |
|---|---|
| 2012-01-01 | $414.00M 10-K · filed 2012-02-23 |
| 2011-01-02 | $294.00M 10-K · filed 2012-02-23 |
| 2010-01-03 | $286.00M 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |